Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Shineway Pharmaceutical GroupFRA:C1S -2.75%88 5-Year Yield-on-Cost % is 10.81 as of Aug. 02, 2026, which is 51% above its 10-year median of 7.16. GuruFocus rates FRA:C1S with a GF Score™ of 88/100 and a GF Value™ of €0.73 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 513 Drug Manufacturers companies, China Shineway Pharmaceutical Group ranks better than 90.06% on this metric.
The historical rank and industry rank for China Shineway Pharmaceutical Group's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:C1S'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.32 Med: 7.16 Max: 22.29
Current: 10.81
During the past 13 years, China Shineway Pharmaceutical Group's highest Yield on Cost was 22.29. The lowest was 2.32. And the median was 7.16.
FRA:C1S's 5-Year Yield-on-Cost % is ranked better than 90.06% of 513
companies
in the Drug Manufacturers industry
Industry Median: 2.32
vs FRA:C1S: 10.81
China Shineway Pharmaceutical Group (FRA:C1S) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
China Shineway Pharmaceutical Group 5-Year Yield-on-Cost % Related Terms
FRA:C1S vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China Shineway Pharmaceutical Group's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Shineway Pharmaceutical Group 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Shineway Pharmaceutical Group's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where China Shineway Pharmaceutical Group's 5-Year Yield-on-Cost % falls into.
China Shineway Pharmaceutical Group 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
China Shineway Pharmaceutical Group (FRA:C1S) has a 5-Year Yield-on-Cost % of 10.81 as of Aug. 02, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on China Shineway Pharmaceutical Group and its competitors. This is 51% above median its historical median of 7.16. Over the past decade, China Shineway Pharmaceutical Group's 5-Year Yield-on-Cost % has ranged from 2.32 to 22.29. According to the industry distribution chart, China Shineway Pharmaceutical Group ranks #51 out of 513 companies in the Drug Manufacturers industry, placing it in the top 9.9%.
Is China Shineway Pharmaceutical Group's 5-Year Yield-on-Cost % too high?
China Shineway Pharmaceutical Group's current 5-Year Yield-on-Cost % of 10.81 is 51% above median its 10-year median of 7.16. Over the past 10 years, this metric has ranged from a low of 2.32 to a high of 22.29. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.32. China Shineway Pharmaceutical Group's value of 10.81 is 365.9% above this industry median. Based on the distribution chart, China Shineway Pharmaceutical Group ranks #51 out of 513 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Shineway Pharmaceutical Group has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Shineway Pharmaceutical Group's 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Shineway Pharmaceutical Group ranks #51 out of 513 companies for 5-Year Yield-on-Cost %. This places China Shineway Pharmaceutical Group in the top 10% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.32. China Shineway Pharmaceutical Group's value of 10.81 is 365.9% above this benchmark. Historically, China Shineway Pharmaceutical Group's own 5-Year Yield-on-Cost % has ranged from 2.32 to 22.29 over the past decade. While the company's 10-year median is 7.16 vs. the industry median of 2.32, China Shineway Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.32, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Shineway Pharmaceutical Group's current 5-Year Yield-on-Cost % of 10.81 is 365.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on China Shineway Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Shineway Pharmaceutical Group's current 5-Year Yield-on-Cost % is 10.81, which is 51% above median its own 10-year median of 7.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Shineway Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, China Shineway Pharmaceutical Group (FRA:C1S) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.73, compared to a current price of €0.89 — trading 21.2% above its estimated fair value. The current 5-Year Yield-on-Cost % is 10.81, which is 51% above median its 10-year median of 7.16 and 365.9% above the Drug Manufacturers industry median of 2.32. China Shineway Pharmaceutical Group's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For China Shineway Pharmaceutical Group (FRA:C1S), the current 5-Year Yield-on-Cost % is 10.81 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Shineway Pharmaceutical Group (FRA:C1S) Overvalued in 2026?
Based on GuruFocus' analysis, China Shineway Pharmaceutical Group stock appears to be overvalued.
The current stock price of €0.89 is trading 21.2% above its estimated GF Value™ of €0.73.
GuruFocus considers China Shineway Pharmaceutical Group to be Modestly Overvalued.
Key valuation signals for FRA:C1S:
5-Year Yield-on-Cost %: 10.81 (51% above median its 10-year median of 7.16)
GF Value™: €0.73 vs. price of €0.89 (21.2% above fair value)
Industry Position: 365.9% above the Drug Manufacturers median (#51 of 513)
No single metric tells the full story. See the FRA:C1S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Shineway Pharmaceutical Group Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, traditional Chinese medicine formula granules, and others, of which injections generate maximum revenue for the company. Geographically, the group operates in the People's Republic of China (PRC) and Hong Kong.
88GF Score
Get the complete analysis for FRA:C1S
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C1S has been successfully added to your 
